{"id":251962,"date":"2023-10-09T00:00:00","date_gmt":"2023-10-09T00:00:00","guid":{"rendered":"http:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0071-biopharma-alzheimers-disease-epidemiology-emerging\/"},"modified":"2026-03-31T10:31:59","modified_gmt":"2026-03-31T10:31:59","slug":"epidcg0071-biopharma-alzheimers-disease-epidemiology-emerging-markets","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/epidcg0071-biopharma-alzheimers-disease-epidemiology-emerging-markets\/","title":{"rendered":"Alzheimer&#8217;s Disease &#8211; Epidemiology &#8211; Emerging Markets"},"content":{"rendered":"<p>Clarivate Epidemiology\u2019s coverage of Alzheimer\u2019s disease (<abbr title=\"Alzheimer's disease\">AD<\/abbr>) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the lifetime prevalence of <abbr title=\"Alzheimer's disease\">AD<\/abbr> for each country, as well as annualized case counts projected to the national population.<\/p>\n<p>Most patient populations are forecast over a period of 10 years for the countries covered in this report. In addition to forecasting lifetime prevalent patient populations, we estimate the number of drug-treatment opportunities in specific lines of therapy in high-income countries.<\/p>\n<p>Clarivate Epidemiology\u2019s <abbr title=\"Alzheimer's disease\">AD<\/abbr> forecast will answer the following questions:<\/p>\n<ul class=\"round-bullets\">\n<li>Of all people diagnosed with <abbr title=\"Alzheimer's disease\">AD<\/abbr>, how many in each high-income country are drug-treated?<\/li>\n<li>How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of <abbr title=\"Alzheimer's disease\">AD<\/abbr> over the forecast period?<\/li>\n<\/ul>\n<p>All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to <abbr title=\"multiple sclerosis\">MS<\/abbr> Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.<\/p>\n<p>Clarivate Epidemiology forecasts the following patient populations:<\/p>\n<ul class=\"round-bullets\">\n<li>Total prevalent cases of asymptomatic <abbr title=\"Alzheimer's disease\">AD<\/abbr>.<\/li>\n<li>Total prevalent cases of symptomatic <abbr title=\"mild cognitive impairment\">MCI<\/abbr> due to <abbr title=\"Alzheimer's disease\">AD<\/abbr> by diagnosis status.<\/li>\n<li>Total prevalent cases of <abbr title=\"Alzheimer's disease\">AD<\/abbr>.<\/li>\n<li>Total prevalent cases of <abbr title=\"Alzheimer's disease\">AD<\/abbr> by severity (mild, moderate, severe).<\/li>\n<li>Total prevalent cases of <abbr title=\"Alzheimer's disease\">AD<\/abbr> by diagnosis status.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"Alzheimer's disease\">AD<\/abbr> by symptom status (agitation, depression, hallucinations).<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"mild cognitive impairment\">MCI<\/abbr> due to <abbr title=\"Alzheimer's disease\">AD<\/abbr> by drug-treatment status.<\/li>\n<li>Diagnosed prevalent cases of <abbr title=\"Alzheimer's disease\">AD<\/abbr> by drug-treatment status.<\/li>\n<li>Diagnosed prevalent cases of mild <abbr title=\"Alzheimer's disease\">AD<\/abbr> by drug-treatment status.<\/li>\n<li>Diagnosed prevalent cases of moderate <abbr title=\"Alzheimer's disease\">AD<\/abbr> by drug-treatment status.<\/li>\n<li>Diagnosed prevalent cases of severe <abbr title=\"Alzheimer's disease\">AD<\/abbr> by drug-treatment status.<\/li>\n<\/ul>\n<p>\u2026 and many more (details available on request).<\/p>\n<p>Note: Coverage may vary by country and region.<\/p>\n","protected":false},"template":"","class_list":["post-251962","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-alzheimers-disease","biopharma-therapy-areas-neurology","biopharma-product-epidemiology","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251962","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251962\/revisions"}],"predecessor-version":[{"id":281332,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/251962\/revisions\/281332"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=251962"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}